Apimeds Pharmaceuticals US (APUS) Equity Average (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Equity Average of $80.8 million for Q4 2025, up 6816.62% on a YoY basis from $1.2 million in Q4 2024, and up 802.37% quarter-over-quarter from $8.9 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Equity Average (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Equity Average for 2 years, with the latest figure at $80.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 6816.62% year-over-year to $80.8 million; the trailing twelve-month figure through Dec 2025 stood at $80.8 million (up 6816.62% YoY), and the FY2025 full-year result was $76.0 million, up 11560.09% from the prior year.
  • Equity Average for Q4 2025 stood at $80.8 million, up from $8.9 million in the prior quarter.
  • The five-year high for Equity Average was $80.8 million in Q4 2025, with the low at -$1.6 million in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Avg. (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 8.07 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 3.32 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 6.50 Bn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 409.63 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 3.33 Bn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 6.52 Bn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.79 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 493.55 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 1.15 Bn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - 80.75 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 80.75 Mn
Sep 30, 2025 8.95 Mn
Jun 30, 2025 3.99 Mn
Mar 31, 2025 -1.56 Mn
Dec 31, 2024 -1.20 Mn
Sep 30, 2024 -880,227.50
Jun 30, 2024 -489,285.50
Mar 31, 2024 -116,367.50